RMD
Neutral signalScored 2026-10-06 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
ResMed Inc.
- Nom
- ResMed Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NYSE
- Capitalisation
- $35.6B
- Employés
- 11,370
- PDG
- Michael J. Farrell
- Site web
- https://www.resmed.com
- Marché
- BSXELMDFSPKFGEHCGNGBYINSP
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 4991 titres (~1110191 USD)
- Insiders
- Farrell Michael J.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$5,294,112
Avg sell (VWAP, 90d window) $221.11 vs last close $238.97 (+8.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$5,294,112 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-08
- Liquidity
- Liquid $255,717,400/day · 20d vol
- Last synced
-
2026-10-17 09:40:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-07 | Farrell Michael J. | Sell · S · 10b5-1 | 4,991 | $226.33 | $1,129,637 | Form 4 |
| 2026-09-08 | Farrell Michael J. | Sell · S · 10b5-1 | 4,991 | $222.44 | $1,110,191 | Form 4 |
| 2026-09-02 | FARRELL PETER C | Sell · S · 10b5-1 | 970 | $234.73 | $227,688 | Form 4 |
| 2026-08-07 | Farrell Michael J. | Sell · S · 10b5-1 | 4,991 | $205.69 | $1,026,596 | Form 4 |
| 2026-08-05 | FARRELL PETER C | Sell · S · 10b5-1 | 8,000 | $225.00 | $1,800,000 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-06-04 | Kelly Morrison | Sale (Full) | $1,001 - $15,000 |
| 2025-04-28 | Kelly Morrison | Sale (Full) | $1,001 - $15,000 |
| 2025-01-13 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2019-02-27 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2019-02-05 | Brad Schneider | Sale (Full) | $250,001 - $500,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
RMD combines exceptional financial health (liquidity 90, fundamentals 85) with a credible earnings catalyst supported by GLP-1 tailwinds, analyst upgrades, and a clear EPS growth target of 12–14%, all converging ahead…
The first sentence of the analysis written for RMD on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $4.2M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $4.2M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 3.10 · operating margin 33%
Suggested stop 235.05, nearest stored support minus 0.5 ATR(1.6% under the last close). Reward/risk to the next stored resistance is 0.88. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.2% | 59.4% | 56.7% | 55.8% | 56.6% | |
| Ebit Margin | 34.5% | 32.6% | 28.0% | 27.5% | 27.5% | |
| Ebitda Margin | 38.0% | 37.2% | 32.7% | 32.2% | 32.9% | |
| Operating Profit Margin | 33.5% | 32.7% | 28.2% | 26.8% | 28.0% | |
| Pretax Profit Margin | 34.0% | 32.6% | 27.0% | 26.1% | 26.8% | |
| Continuous Operations Profit Margin | 26.9% | 27.2% | 21.8% | 21.3% | 21.8% | |
| Net Profit Margin | 26.9% | 27.2% | 21.8% | 21.3% | 21.8% | |
| Bottom Line Profit Margin | 26.9% | 27.2% | 21.8% | 21.3% | 21.8% | |
| Current Ratio | 3.100 | 3.440 | 2.589 | 3.122 | 2.802 | |
| Quick Ratio | 2.422 | 2.530 | 1.686 | 1.806 | 1.723 | |
| Solvency Ratio | 0.723 | 0.742 | 0.616 | 0.417 | 0.561 | |
| Cash Ratio | 1.053 | 1.187 | 0.262 | 0.300 | 0.397 | |
| Price To Earnings Ratio | 18.667 | 27.016 | 26.937 | 35.703 | 39.257 | |
| Price To Earnings Growth Ratio | 2.003 | 0.718 | 2.010 | 2.444 | 0.620 | |
| Forward Price To Earnings Growth Ratio | 2.003 | 0.718 | 2.010 | 2.444 | 0.620 | |
| Price To Earnings Diluted Ratio | 18.738 | 27.129 | 27.014 | 35.878 | 39.553 | |
| Price To Earnings Diluted Growth Ratio | 2.002 | 0.725 | 1.982 | 2.407 | 0.622 | |
| Price To Book Ratio | 4.282 | 6.343 | 5.650 | 7.765 | 9.111 | |
| Price To Sales Ratio | 4.988 | 7.355 | 5.866 | 7.594 | 8.557 | |
| Price To Free Cash Flow Ratio | 17.096 | 22.779 | 21.365 | 57.336 | 156.935 | |
| Price To Operating Cash Flow Ratio | 15.616 | 21.611 | 19.614 | 46.254 | 87.199 | |
| Debt To Assets Ratio | 0.092 | 0.104 | 0.127 | 0.234 | 0.180 | |
| Debt To Equity Ratio | 0.125 | 0.143 | 0.180 | 0.383 | 0.273 | |
| Debt To Capital Ratio | 0.111 | 0.125 | 0.152 | 0.277 | 0.214 | |
| Long Term Debt To Capital Ratio | 0.057 | 0.099 | 0.125 | 0.257 | 0.185 | |
| Financial Leverage Ratio | 1.361 | 1.370 | 1.413 | 1.635 | 1.516 | |
| Working Capital Turnover Ratio | 2.088 | 2.617 | 3.066 | 2.962 | 3.756 | |
| Operating Cash Flow Ratio | 1.294 | 1.719 | 1.539 | 0.914 | 0.509 | |
| Operating Cash Flow Sales Ratio | 0.319 | 0.340 | 0.299 | 0.164 | 0.098 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.913 | 0.949 | 0.918 | 0.807 | 0.556 | |
| Debt Service Coverage Ratio | 6.056 | 72.706 | 23.193 | 20.158 | 30.892 | |
| Interest Coverage Ratio | 65.199 | 133.663 | 28.877 | 23.890 | 44.832 | |
| Short Term Operating Cash Flow Coverage Ratio | 6.947 | 176.928 | 141.541 | 70.016 | 35.412 | |
| Operating Cash Flow Coverage Ratio | 2.186 | 2.056 | 1.603 | 0.439 | 0.383 | |
| Capital Expenditure Coverage Ratio | 11.555 | 19.491 | 12.200 | 5.174 | 2.250 | |
| Dividend Paid And Capex Coverage Ratio | 3.569 | 4.371 | 3.528 | 1.767 | 0.875 | |
| Dividend Payout Ratio | 0.230 | 0.222 | 0.277 | 0.288 | 0.315 | |
| Enterprise Value Multiple | 12.839 | 19.596 | 18.336 | 24.595 | 26.570 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.2% | ▲1.8% | ▲3.2% |
| Ebit Margin | 34.5% | ▲1.9% | ▲4.5% |
| Ebitda Margin | 38.0% | ▲0.8% | ▲3.4% |
| Operating Profit Margin | 33.5% | ▲0.7% | ▲3.6% |
| Pretax Profit Margin | 34.0% | ▲1.4% | ▲4.7% |
| Continuous Operations Profit Margin | 26.9% | ▼-0.3% | ▲3.1% |
| Net Profit Margin | 26.9% | ▼-0.3% | ▲3.1% |
| Bottom Line Profit Margin | 26.9% | ▼-0.3% | ▲3.1% |
| Current Ratio | 3.100 | ▼-0.340 | ▲0.089 |
| Quick Ratio | 2.422 | ▼-0.107 | ▲0.389 |
| Solvency Ratio | 0.723 | ▼-0.019 | ▲0.111 |
| Cash Ratio | 1.053 | ▼-0.134 | ▲0.413 |
| Price To Earnings Ratio | 18.667 | ▼-8.349 | ▼-10.849 |
| Price To Earnings Growth Ratio | 2.003 | ▲1.285 | ▲0.444 |
| Forward Price To Earnings Growth Ratio | 2.003 | ▲1.285 | ▲0.444 |
| Price To Earnings Diluted Ratio | 18.738 | ▼-8.391 | ▼-10.924 |
| Price To Earnings Diluted Growth Ratio | 2.002 | ▲1.277 | ▲0.455 |
| Price To Book Ratio | 4.282 | ▼-2.061 | ▼-2.348 |
| Price To Sales Ratio | 4.988 | ▼-2.367 | ▼-1.884 |
| Price To Free Cash Flow Ratio | 17.096 | ▼-5.683 | ▼-38.007 |
| Price To Operating Cash Flow Ratio | 15.616 | ▼-5.994 | ▼-22.443 |
| Debt To Assets Ratio | 0.092 | ▼-0.012 | ▼-0.055 |
| Debt To Equity Ratio | 0.125 | ▼-0.017 | ▼-0.095 |
| Debt To Capital Ratio | 0.111 | ▼-0.013 | ▼-0.065 |
| Long Term Debt To Capital Ratio | 0.057 | ▼-0.042 | ▼-0.088 |
| Financial Leverage Ratio | 1.361 | ▼-0.008 | ▼-0.098 |
| Working Capital Turnover Ratio | 2.088 | ▼-0.529 | ▼-0.810 |
| Operating Cash Flow Ratio | 1.294 | ▼-0.424 | ▲0.099 |
| Operating Cash Flow Sales Ratio | 0.319 | ▼-0.021 | ▲0.075 |
| Free Cash Flow Operating Cash Flow Ratio | 0.913 | ▼-0.035 | ▲0.085 |
| Debt Service Coverage Ratio | 6.056 | ▼-66.649 | ▼-24.545 |
| Interest Coverage Ratio | 65.199 | ▼-68.465 | ▲5.907 |
| Short Term Operating Cash Flow Coverage Ratio | 6.947 | ▼-169.981 | ▼-79.222 |
| Operating Cash Flow Coverage Ratio | 2.186 | ▲0.130 | ▲0.853 |
| Capital Expenditure Coverage Ratio | 11.555 | ▼-7.937 | ▲1.421 |
| Dividend Paid And Capex Coverage Ratio | 3.569 | ▼-0.802 | ▲0.747 |
| Dividend Payout Ratio | 0.230 | ▲0.008 | ▼-0.037 |
| Enterprise Value Multiple | 12.839 | ▼-6.757 | ▼-7.548 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $28.20B | $37.85B | $27.48B | $32.07B | $30.62B | |
| Enterprise value | $27.56B | $37.50B | $28.12B | $33.42B | $31.26B | |
| EV / Sales | 4.87x | 7.29x | 6.00x | 7.91x | 8.74x | |
| EV / Op. cash flow | 15.26x | 21.41x | 20.07x | 48.20x | 89.03x | |
| EV / Free cash flow | 16.71x | 22.56x | 21.86x | 59.75x | 160.24x | |
| EV / EBITDA | 12.84x | 19.60x | 18.34x | 24.59x | 26.57x | |
| Net debt / EBITDA | -0.30x | -0.19x | 0.41x | 0.99x | 0.55x | |
| Current ratio | 3.10x | 3.44x | 2.59x | 3.12x | 2.80x | |
| Income quality | 1.19x | 1.25x | 1.37x | 0.77x | 0.45x | |
| Graham number | $104 | $93 | $72 | $62 | $53 | |
| Graham net-net | $2 | $1 | -$5 | -$9 | -$5 | |
| Tax burden | 79.4% | 83.5% | 80.7% | 81.5% | 81.2% | |
| Interest burden | 98.5% | 100.0% | 96.5% | 94.8% | 97.7% | |
| Working capital | $2.93B | $2.49B | $1.45B | $1.61B | $1.24B | |
| Invested capital | $7.03B | $6.72B | $5.47B | $5.60B | $4.16B | |
| Return on assets | 17.0% | 17.1% | 14.9% | 13.3% | 15.3% | |
| Operating ROA | 22.1% | 22.4% | 19.4% | 19.1% | 20.4% | |
| Return on tangible assets | 27.2% | 30.0% | 28.8% | 26.2% | 27.7% | |
| Return on equity | 23.1% | 23.5% | 21.0% | 21.7% | 23.2% | |
| Return on invested capital | 19.1% | 19.6% | 17.8% | 15.3% | 18.3% | |
| Return on capital employed | 25.0% | 23.6% | 22.1% | 18.9% | 22.7% | |
| Earnings yield | 5.4% | 3.7% | 3.7% | 2.8% | 2.5% | |
| Free cash flow yield | 5.8% | 4.4% | 4.7% | 1.7% | 0.6% | |
| Capex / Op. cash flow | 8.7% | 5.1% | 8.2% | 19.3% | 44.4% | |
| Capex / Depreciation | 64.0% | 38.1% | 53.1% | 67.8% | 80.5% | |
| Capex / Sales | 2.8% | 1.7% | 2.5% | 3.2% | 4.4% | |
| SG&A / Sales | 14.5% | 19.3% | 19.6% | 20.7% | 20.7% | |
| R&D / Sales | 6.7% | 6.4% | 6.6% | 6.8% | 7.1% | |
| Stock comp / Sales | 1.8% | 1.8% | 1.7% | 1.7% | 1.8% | |
| Intangibles / Total assets | 37.5% | 43.0% | 48.4% | 49.2% | 44.8% | |
| Days sales outstanding | 67d | 70d | 65d | 61d | 59d | |
| Days payables outstanding | 51d | 49d | 43d | 29d | 37d | |
| Operating cycle | 224d | 232d | 213d | 256d | 234d | |
| Cash conversion cycle | 173d | 184d | 170d | 227d | 196d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-01 Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 2026-09-22 ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell said the company has issued guidance for 5% to 7% core constant-currency revenue growth, including an
- 2026-09-21 ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.
- 2026-09-17 Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 shares of the medical equipment provider''s stock after acquiring an additional 3,555 shares during the period. Engineers Gate
- 2026-09-15 Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like. Setbacks for competitors have positioned ResMed to capture more market share.
- 2026-09-15 Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A ''Hoax'' AI regulation odds have sharply declined after Trump dismissed AI takeover concerns during a public call with Nvidia (NVDA) CEO Jensen Huang. ResMed (RMD) was upgraded to Outperform by RBC Capital Markets, with a price target raised to $262, citing strong Q4 results and expected high-single-digit EPS growth.
- 2026-09-15 ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-15 Is This the Right Time to Retain Resmed Stock in Your Portfolio? RMD''s software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
- 2026-09-15 Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More Markets are rattled ahead of Wednesday''s Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.
- 2026-09-10 ResMed: A Significant Upside Despite The Perceived Risk ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips'' US return poses the most credible threat.